Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
129 shown of 6,033 total abstracts
  1. Abstract 48492026-06-01 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-974 study)
    R. Herbst, A. Spira, H. Rugo, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract 55272026-06-03 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-897 study)
    F. Andre, C. Robert, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  3. Abstract 14212026-06-05 · 21:45 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-293 study)
    T. Mok, A. Spira, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  4. Abstract 42212026-06-04 · 15:45 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    J. Cortes, A. Spira, P. Schmid, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  5. Abstract 12572026-06-05 · 20:45 CT · S406
    KEYNOTE-120: Keytruda (pembrolizumab) neoadjuvant in TNBC
    H. Borghaei, S. Tolaney · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  6. Abstract 40712026-06-04 · 14:30 CT · S100A
    ASCENT-65: Trodelvy (sacituzumab govitecan) neoadjuvant in urothelial carcinoma
    S. Peters, T. Mok, M. Reck, et al. · Royal Marsden Hospital
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 41772026-06-03 · 16:45 CT · Arie Crown Theater
    Long-term follow-up of Padcev 2L for urothelial carcinoma: EV-201
    S. Antonia, P. Schmid · Karolinska Institute
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract 96042026-06-04 · 21:00 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Peters, R. Herbst, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract 99732026-06-01 · 14:45 CT · S406
    PACIFIC-382: Imfinzi (durvalumab) 3L+ in NSCLC
    F. Andre, C. Robert, J. Cortes · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 95472026-06-03 · 20:45 CT · E450
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-918 study)
    G. Curigliano, F. Andre · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 16692026-06-02 · 18:15 CT · E450
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-923
    C. Saura, H. Rugo, S. Antonia, et al. · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  12. Abstract 46022026-06-04 · 13:15 CT · S406
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    C. Saura, J. Brahmer, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 93592026-06-01 · 19:00 CT · S406
    Quality of life outcomes with Imfinzi in patients with NSCLC
    C. Saura, M. Krop, A. Spira · Karolinska Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract 91442026-06-05 · 19:00 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-825
    S. Modi, J. Cortes, P. Schmid, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  15. Abstract 10822026-06-04 · 18:45 CT · Hall B1
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-400
    H. Rugo, S. Peters, M. Krop, et al. · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  16. Abstract 19812026-06-04 · 13:30 CT · S100A
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-17
    R. Herbst, M. Krop, N. Rizvi · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  17. Abstract 60132026-06-01 · 19:30 CT · S100A
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-624
    L. Paz-Ares, C. Saura · National Cancer Center Japan
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  18. Abstract 14032026-06-03 · 13:30 CT · Hall B1
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-674
    H. Rugo, N. Rizvi, E. Winer · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  19. Abstract 95452026-06-05 · 21:00 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    H. Rugo, S. Antonia, N. Rizvi · Chinese University of Hong Kong
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 13032026-06-03 · 15:45 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-271
    E. Winer, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  21. Abstract 15942026-06-02 · 21:15 CT · E450
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    S. Peters, M. Krop, M.C. Garassino · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  22. Abstract 12052026-06-05 · 18:00 CT · Hall B1
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-163
    J. Cortes, J. Brahmer, G. Curigliano, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  23. Abstract 13092026-06-04 · 21:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-468
    R. Herbst, L. Paz-Ares, M. Krop, et al. · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  24. Abstract 41602026-06-03 · 19:00 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with gastric
    C. Saura, M. Krop, S. Tolaney · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  25. Abstract 17342026-06-03 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-23 study)
    S. Peters, L. Paz-Ares, H. Rugo, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  26. Abstract 13722026-06-01 · 19:45 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    E. Winer, M.C. Garassino · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  27. Abstract 41462026-06-02 · 19:15 CT · S406
    Long-term follow-up of Tecentriq neoadjuvant for HCC: IMpower-534
    S. Modi, L. Paz-Ares, S. Tolaney · Cleveland Clinic
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  28. Abstract 17792026-06-04 · 13:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-979
    C. Saura, S. Antonia · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  29. Abstract 94822026-06-01 · 15:15 CT · S406
    Quality of life outcomes with Keytruda in patients with NSCLC
    S. Tolaney, S. Antonia · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 19602026-06-05 · 18:45 CT · S100A
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-300
    F. Andre, P. Schmid · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  31. Abstract 16412026-06-01 · 14:15 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    J. Brahmer, E. Winer, S. Peters, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  32. Abstract 13372026-06-05 · 18:00 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-706
    H. Rugo, S. Tolaney, S. Peters · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  33. Abstract 96702026-06-03 · 21:00 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-969 study)
    S. Peters, M.C. Garassino, S. Modi, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  34. Abstract 11072026-06-01 · 18:00 CT · Hall B1
    MONARCH-940: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    C. Saura, S. Tolaney, S. Modi, et al. · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  35. Abstract 42772026-06-05 · 16:00 CT · S406
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    S. Antonia, J. Brahmer · Mayo Clinic
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 12182026-06-05 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-858 study)
    C. Robert, H. Borghaei · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  37. Abstract 13882026-06-01 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-796
    M. Krop, S. Tolaney, H. Rugo · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  38. Abstract 93002026-06-05 · 15:45 CT · E450
    FLAURA-193: Tagrisso (osimertinib) maintenance in NSCLC
    F. Andre, J. Cortes, L. Paz-Ares · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  39. Abstract 97452026-06-02 · 19:45 CT · S100A
    FLAURA-407: Tagrisso (osimertinib) 1L in NSCLC
    A. Spira, E. Winer, H. Rugo, et al. · National Cancer Center Japan
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  40. Abstract 18622026-06-03 · 15:30 CT · Hall B1
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    F. Andre, C. Saura · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  41. Abstract 15002026-06-05 · 20:00 CT · Hall B1
    ASCENT-80: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    C. Saura, A. Spira, J. Cortes · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  42. Abstract 51362026-06-02 · 15:00 CT · S100A
    Quality of life outcomes with Lynparza in patients with prostate
    M. Reck, C. Robert · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  43. Abstract 19202026-06-03 · 16:00 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-895
    S. Peters, S. Tolaney, H. Borghaei · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  44. Abstract 12712026-06-01 · 13:30 CT · E450
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-402
    S. Peters, G. Curigliano, C. Robert · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  45. Abstract 16402026-06-05 · 15:00 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-692 study)
    J. Brahmer, G. Curigliano, S. Tolaney · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  46. Abstract 92832026-06-05 · 20:00 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-535
    J. Cortes, F. Andre, M.C. Garassino · Institut Gustave Roussy
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  47. Abstract 19122026-06-01 · 16:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-992
    C. Saura, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  48. Abstract 47022026-06-02 · 20:45 CT · E450
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-339 study)
    H. Borghaei, M. Krop, J. Cortes, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  49. Abstract 54372026-06-01 · 15:15 CT · E450
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-696 study)
    J. Cortes, M. Reck · University of Chicago
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  50. Abstract 96862026-06-01 · 20:15 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-601
    H. Borghaei, F. Andre, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  51. Abstract 96092026-06-05 · 18:45 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-331 study)
    J. Cortes, H. Borghaei · Dana-Farber Cancer Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  52. Abstract 19192026-06-03 · 18:45 CT · Hall B1
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-844
    G. Curigliano, J. Brahmer, P. Schmid, et al. · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  53. Abstract 12282026-06-03 · 13:00 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-987
    S. Antonia, M. Krop, C. Saura · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  54. Abstract 14512026-06-01 · 19:30 CT · E450
    PALOMA-669: Ibrance (palbociclib) maintenance in HR+ breast cancer
    L. Paz-Ares, C. Robert, J. Brahmer, et al. · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  55. Abstract 97752026-06-05 · 14:45 CT · E450
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-16 study)
    J. Brahmer, F. Andre, M. Krop, et al. · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  56. Abstract 11742026-06-01 · 13:15 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    L. Paz-Ares, S. Modi, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  57. Abstract 17792026-06-02 · 14:15 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    F. Andre, S. Tolaney, M.C. Garassino, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  58. Abstract 42442026-06-02 · 15:00 CT · E450
    Long-term follow-up of Enhertu neoadjuvant for gastric: DESTINY-Breast-379
    J. Brahmer, S. Peters · Massachusetts General Hospital
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  59. Abstract 93322026-06-01 · 16:00 CT · E450
    IMpower-795: Tecentriq (atezolizumab) 2L in NSCLC
    N. Rizvi, R. Herbst · Mayo Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  60. Abstract 92422026-06-01 · 19:15 CT · S406
    Quality of life outcomes with Opdivo in patients with NSCLC
    H. Rugo, M. Krop · Mayo Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  61. Abstract 10002026-06-02 · 21:00 CT · E450
    IMpower-747: Tecentriq (atezolizumab) adjuvant in TNBC
    G. Curigliano, A. Spira, S. Modi · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  62. Abstract 90282026-06-02 · 20:00 CT · E450
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-496
    S. Peters, T. Mok · MD Anderson Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  63. Abstract 95632026-06-04 · 19:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-354
    J. Brahmer, G. Curigliano, P. Schmid, et al. · Massachusetts General Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract 11122026-06-05 · 19:15 CT · S406
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-344
    L. Paz-Ares, M.C. Garassino, S. Modi, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  65. Abstract 95052026-06-05 · 20:15 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    M. Reck, C. Robert, S. Tolaney, et al. · Massachusetts General Hospital
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  66. Abstract 19632026-06-05 · 16:15 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-339 study)
    H. Rugo, J. Cortes · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  67. Abstract 94582026-06-04 · 16:15 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    C. Saura, J. Cortes, E. Winer · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  68. Abstract 16982026-06-03 · 18:00 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-14
    N. Rizvi, S. Tolaney, S. Peters · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  69. Abstract 11642026-06-04 · 13:15 CT · E450
    Quality of life outcomes with Trodelvy in patients with TNBC
    H. Rugo, R. Herbst · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  70. Abstract 17402026-06-01 · 18:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-198
    S. Peters, M. Krop · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  71. Abstract 94262026-06-04 · 20:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-960
    F. Andre, M. Reck, C. Saura, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  72. Abstract 47212026-06-02 · 15:30 CT · E450
    Long-term follow-up of Trodelvy 2L for urothelial carcinoma: ASCENT-233
    C. Robert, S. Peters, M. Krop · Chinese University of Hong Kong
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  73. Abstract 14842026-06-05 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-603 study)
    S. Modi, J. Brahmer, A. Spira, et al. · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  74. Abstract 92032026-06-04 · 19:30 CT · Hall B1
    Long-term follow-up of Opdivo 2L for NSCLC: CheckMate-442
    M. Reck, S. Tolaney, F. Andre, et al. · University of Chicago
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  75. Abstract 102852026-06-04 · 18:15 CT · Arie Crown Theater
    KEYNOTE-737: Keytruda (pembrolizumab) 2L in metastatic melanoma
    S. Peters, R. Herbst, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumMelanoma📄🖼️
  76. Abstract 13972026-06-05 · 13:15 CT · S406
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-621
    R. Herbst, J. Brahmer, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  77. Abstract 43032026-06-03 · 20:45 CT · E450
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-482 study)
    H. Rugo, R. Herbst · Institut Gustave Roussy
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  78. Abstract 19802026-06-01 · 13:00 CT · E450
    DESTINY-Breast-900: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    M. Krop, N. Rizvi · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  79. Abstract 97442026-06-02 · 13:15 CT · S100A
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-172
    A. Spira, H. Rugo, M. Krop, et al. · National Cancer Center Japan
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  80. Abstract 58602026-06-05 · 16:30 CT · S406
    OlympiA-525: Lynparza (olaparib) 3L+ in ovarian
    J. Brahmer, H. Borghaei, M. Reck, et al. · Cleveland Clinic
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  81. Abstract 19462026-06-05 · 18:30 CT · Arie Crown Theater
    PALOMA-145: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    M.C. Garassino, C. Robert, N. Rizvi · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  82. Abstract 19582026-06-05 · 18:45 CT · S406
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    J. Brahmer, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  83. Abstract 47552026-06-05 · 19:00 CT · E450
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-946
    C. Robert, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  84. Abstract 90272026-06-05 · 20:15 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    R. Herbst, C. Robert, P. Schmid, et al. · University of Chicago
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  85. Abstract 92882026-06-05 · 15:15 CT · E450
    PACIFIC-576: Imfinzi (durvalumab) neoadjuvant in NSCLC
    M.C. Garassino, S. Antonia, J. Brahmer, et al. · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 19062026-06-03 · 19:30 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    T. Mok, J. Brahmer, M. Krop, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  87. Abstract 43322026-06-04 · 13:45 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-368
    S. Peters, G. Curigliano, N. Rizvi, et al. · Cleveland Clinic
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  88. Abstract 44782026-06-01 · 18:45 CT · S100A
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-950
    L. Paz-Ares, J. Brahmer · University of Chicago
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  89. Abstract 16312026-06-05 · 15:15 CT · Arie Crown Theater
    OlympiA-357: Lynparza (olaparib) maintenance in HR+ breast cancer
    J. Cortes, F. Andre, S. Tolaney · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  90. Abstract 12132026-06-03 · 13:45 CT · E450
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-523
    M.C. Garassino, N. Rizvi, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  91. Abstract 41092026-06-03 · 14:30 CT · Hall B1
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    S. Modi, L. Paz-Ares · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  92. Abstract 99832026-06-02 · 21:45 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    C. Saura, G. Curigliano, N. Rizvi, et al. · Karolinska Institute
    Clinical Science SymposiumMelanoma📄🖼️
  93. Abstract 16882026-06-05 · 20:00 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-727 study)
    M. Krop, F. Andre, S. Antonia, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  94. Abstract 17222026-06-05 · 15:30 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-582 study)
    P. Schmid, N. Rizvi, C. Robert, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  95. Abstract 18562026-06-05 · 15:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-859
    J. Brahmer, L. Paz-Ares, A. Spira · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  96. Abstract 17552026-06-03 · 21:30 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-713
    G. Curigliano, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  97. Abstract 16312026-06-02 · 19:00 CT · S406
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-34
    G. Curigliano, A. Spira, M. Reck · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  98. Abstract 54162026-06-02 · 18:30 CT · S100A
    Long-term follow-up of Lynparza 2L for prostate: OlympiA-456
    J. Brahmer, T. Mok, S. Modi · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  99. Abstract 10762026-06-02 · 21:30 CT · Hall B1
    ASCENT-790: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    G. Curigliano, S. Antonia, S. Tolaney, et al. · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  100. Abstract 18062026-06-01 · 21:45 CT · S100A
    IMpower-247: Tecentriq (atezolizumab) maintenance in TNBC
    R. Herbst, J. Cortes, P. Schmid, et al. · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  101. Abstract 48792026-06-05 · 13:15 CT · Hall B1
    EV-666: Padcev (enfortumab vedotin) 2L in urothelial carcinoma
    J. Cortes, S. Modi · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  102. Abstract 10282026-06-03 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-170
    R. Herbst, C. Saura, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  103. Abstract 52662026-06-04 · 19:00 CT · E450
    Long-term follow-up of Lynparza 1L for prostate: OlympiA-695
    A. Spira, T. Mok, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Prostate📄🖼️
  104. Abstract 49932026-06-01 · 15:30 CT · S406
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-220
    S. Modi, G. Curigliano · Cleveland Clinic
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  105. Abstract 92052026-06-05 · 15:15 CT · S406
    PACIFIC-688: Imfinzi (durvalumab) 2L in SCLC
    J. Cortes, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  106. Abstract 15542026-06-04 · 16:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-332 study)
    J. Cortes, C. Saura, S. Antonia, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  107. Abstract 40262026-06-03 · 13:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-307 study)
    M. Krop, J. Cortes, C. Saura · Cleveland Clinic
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  108. Abstract 96302026-06-02 · 14:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-685
    J. Brahmer, H. Rugo, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  109. Abstract 58752026-06-01 · 15:00 CT · S100A
    OlympiA-401: Lynparza (olaparib) maintenance in ovarian
    C. Robert, G. Curigliano, L. Paz-Ares · MD Anderson Cancer Center
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  110. Abstract 92372026-06-01 · 21:30 CT · Hall B1
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-594
    C. Saura, J. Cortes, S. Tolaney, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  111. Abstract 45402026-06-04 · 13:00 CT · Hall B1
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-809
    M. Reck, A. Spira, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  112. Abstract 61702026-06-01 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-6 study)
    R. Herbst, G. Curigliano, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  113. Abstract 49402026-06-05 · 20:00 CT · Hall B1
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-864
    S. Peters, H. Rugo, G. Curigliano · Institut Gustave Roussy
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  114. Abstract 67862026-06-04 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-798
    R. Herbst, F. Andre, S. Tolaney, et al. · National Cancer Center Japan
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  115. Abstract 67572026-06-03 · 15:30 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-561
    S. Modi, C. Robert, F. Andre, et al. · Mayo Clinic
    Clinical Science SymposiumGenitourinary Cancer—Kidney/Bladder📄🖼️
  116. Abstract 45952026-06-04 · 18:15 CT · S406
    Quality of life outcomes with Imfinzi in patients with biliary tract
    S. Tolaney, F. Andre, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumGastrointestinal Cancer📄🖼️
  117. Abstract 95402026-06-01 · 18:00 CT · Arie Crown Theater
    DESTINY-Breast-769: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    H. Rugo, S. Modi · Chinese University of Hong Kong
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  118. Abstract 92022026-06-04 · 16:45 CT · S406
    Long-term follow-up of Imfinzi 3L+ for SCLC: PACIFIC-41
    P. Schmid, M. Krop, E. Winer, et al. · Cleveland Clinic
    Clinical Science SymposiumLung Cancer—Small Cell📄🖼️
  119. Abstract 60332026-06-05 · 18:00 CT · S100A
    OlympiA-942: Lynparza (olaparib) 1L in ovarian
    A. Spira, F. Andre, S. Tolaney · University of Chicago
    Clinical Science SymposiumGynecologic Cancer📄🖼️
  120. Abstract 90752026-06-03 · 18:15 CT · Hall B1
    IMpower-385: Tecentriq (atezolizumab) 2L in NSCLC
    L. Paz-Ares, R. Herbst · Princess Margaret Cancer Centre
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  121. Abstract 13632026-06-03 · 15:15 CT · E450
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-103
    H. Rugo, A. Spira · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  122. Abstract 10682026-06-04 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-974 study)
    S. Modi, J. Brahmer · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  123. Abstract 16312026-06-02 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-434 study)
    F. Andre, H. Rugo · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  124. Abstract 91242026-06-04 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-541 study)
    S. Antonia, M. Krop · Karolinska Institute
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  125. Abstract 15172026-06-02 · 19:00 CT · S406
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-124
    H. Borghaei, J. Brahmer, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  126. Abstract 17272026-06-03 · 14:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-802
    S. Antonia, J. Cortes, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  127. Abstract 92682026-06-01 · 20:15 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-909
    C. Saura, M.C. Garassino, H. Borghaei, et al. · University of Chicago
    Clinical Science SymposiumLung Cancer—Non-Small Cell Metastatic📄🖼️
  128. Abstract 10342026-06-04 · 13:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-889
    C. Saura, M.C. Garassino, J. Cortes, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  129. Abstract 101782026-06-05 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-94
    P. Schmid, L. Paz-Ares · Institut Gustave Roussy
    Clinical Science SymposiumMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.